

Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready to Start	Date of First Patient Recruited	Non-Confirmation Status	Duration between Date site selected and First Patient (days)	A - Permissions delayed/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability / issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:
19/LO/0452	250324	CASTLE: Randomised factorial design controlled trial comparing carbamazepine, levetiracetam or active monitoring combined with or without sleep behaviour intervention in treatment naive children with rolandic epilepsy	27/03/2019	08/08/2019	02/05/2019	10/09/2019	17/09/2019	04/10/2019	11/02/2020		187							Y				Four participants were screened and approached, however participants rejected the study. Site continued to screen and approach potential participants and recruited the first patient in February 2020. Trial has since been closed early due to low numbers, trial in the process of being redesigned	NHS Provider
19/LO/0236 (a)	230338	The Effect of Higher Protein Dosing in Critically Ill Patients: A Multicenter Registry-based Randomized Trial - The EFFORT Trial	25/04/2019	11/09/2019	01/07/2019	06/12/2019	10/12/2019	11/12/2019	08/01/2020		119			Y								Sponsor delays with HRA approval for our site to be added (This record is for St Richard's Hospital Principal Investigator site)	Sponsor
19/LO/0236 (b)	230338	The Effect of Higher Protein Dosing in Critically Ill Patients: A Multicenter Registry-based Randomized Trial - The EFFORT Trial	25/04/2019	11/09/2019	01/07/2019	06/12/2019	10/12/2019	11/12/2019	22/01/2020		133			Y								Sponsor delays with HRA approval for our site to be added (This record is for Worthing Hospital's Principal Investigator site)	Sponsor
19/NE/0215	234453	Myeloma XIV (FITNEss). Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma: A phase III trial to compare standard and frailty-adjusted induction therapy with ixazomib, lenalidomide and dexamethasone (IRD) and maintenance lenalidomide (R) to lenalidomide plus ixazomib (R+I).	28/06/2019	02/12/2019	07/11/2019	21/01/2020	19/02/2020	06/08/2020	29/09/2020		302			Y								The Sponsor were not ready to open sites; they hoped to open sites in February 2020. Sponsor due to open sites in February 2020, however this got delayed further and in March 2020 the Sponsor put this study on hold due to the global pandemic. First patient recruited after restart at site	Sponsor
20/EE/0101	281712	Randomised Evaluation of COVID-19 Therapy (RECOVERY)	17/03/2020	17/03/2020	17/03/2020	13/03/2020	25/03/2020	25/03/2020	01/04/2020		15												